Health · 40 views
GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes
For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering…
Summary
For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Study identifies potential new treatment targets for the most common type of bowel cancerContinue reading
- STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclearContinue reading
- Infants' Maternal Measles Protection May Not Last Until First MMR DoseContinue reading
- What Did Leaked Data on an mRNA Vaccine Show?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow